Trial Review

The ANZCTR website is back online for trial registration and updates. We apologise for any inconvenience caused while the site was inactive.


With activity expected to increase on the ANZCTR again, there may be extended wait times while we process pending studies, with priority being given to those trials submitted in February. Thank you for your patience.


Reset your password and enable multi-factor authentication (MFA)


For ANZCTR account holders: to help ensure the cyber safety of your account, you’ll need to reset your password and set-up multi-factor authentication (MFA) as per the instructions below.


  1. Go to the Login page, click ‘reset password’ and follow the instructions.
  2. Check your email for the link to set a new password.
  3. Create a new password that meets requirements.
  4. Return to the Login page and enter your new password. A verification code will be sent to your email.
  5. Check your email for the code and enter it on the Login page. If the code is entered incorrectly, you can re-enter the correct one or request a new one.

Learn more about MFA and its importance on the Australian Signals Directorate website.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12621001149853
Ethics application status
Approved
Date submitted
6/07/2021
Date registered
26/08/2021
Date last updated
31/08/2023
Date data sharing statement initially provided
26/08/2021
Type of registration
Prospectively registered

Titles & IDs
Public title
The effect of increased fibre intake on HbA1c and peripheral immune cells in diabetes
Scientific title
The effect of increased fibre intake on HbA1c and peripheral immune cells in diabetes
Secondary ID [1] 298412 0
None
Universal Trial Number (UTN)
U1111-1267-4663
Trial acronym
None
Linked study record
None

Health condition
Health condition(s) or problem(s) studied:
Type 2 Diabetes 313119 0
Condition category
Condition code
Metabolic and Endocrine 320262 320262 0 0
Diabetes

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
This is an intervention study of a fibre supplement (Metamucil, psyllium husk) 6.8g twice daily (total dose 13.6g) for 12 weeks. This is given as a powder and dissolved in 200ml cold water. Packaging will be returned to determine compliance.
Intervention code [1] 314660 0
Treatment: Other
Comparator / control treatment
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 320303 0
HbA1c from blood sample
Timepoint [1] 320303 0
Baseline, 12 weeks after the start of the intervention
Secondary outcome [1] 371121 0
fasting glucose from blood sample
Timepoint [1] 371121 0
Baseline, 12 weeks after the start of the intervention
Secondary outcome [2] 397701 0
fasting blood lipids from blood sample
Timepoint [2] 397701 0
Baseline, 12 weeks after the start of the intervention
Secondary outcome [3] 397703 0
Baseline, Peripheral blood immune cell functional change - exploratory outcome, from blood sample.
Timepoint [3] 397703 0
Baseline, 12 weeks after the start of the intervention and 14 weeks after the start of the intervention

Eligibility
Key inclusion criteria
Males and females 18 years - 85 years
Pre-diabetes or type 2 diabetes with HbA1c between 45 mmol/mol and 70 mmol/mol inclusive from a test within the last 3 months. At least 75% of participants will have an HbA1c >50mmol/mol.
A low fibre intake of <18g/day for women or 22g/day for men using the Massey University DFiT fibre screening tool.
Willing to maintain stable diet and exercise patterns throughout the study
Stable medication for lipid lowering and hypertension for 3 months prior to study entry
Minimum age
18 Years
Maximum age
85 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Previous bariatric surgery
Pregnancy or breast feeding
Immune altering medications – long-term antibiotics, steroids, immune suppressants
Insulin use
Swallowing difficulties (therefore unable to consume Metamucil)
Unable to consume psyllium soluble fibre for any reason – allergy, physical difficulties

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
Analysis will be by a mixed linear model with random effects for participants and fixed effects for baseline HbA1c.

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
13/09/2021
Actual
17/02/2022
Date of last participant enrolment
Anticipated
30/12/2022
Actual
19/12/2022
Date of last data collection
Anticipated
Actual
12/04/2023
Sample size
Target
30
Accrual to date
Final
30
Recruitment outside Australia
Country [1] 21570 0
New Zealand
State/province [1] 21570 0
Wellington

Funding & Sponsors
Funding source category [1] 302959 0
Government body
Name [1] 302959 0
National Science Challenge High Value Nutrition
Country [1] 302959 0
New Zealand
Primary sponsor type
Hospital
Name
Capital and Coast DHB
Address
Clinical Trials Unit
Wellington Hospital
Private Bag 7902
Wellington 6021
Country
New Zealand
Secondary sponsor category [1] 302916 0
None
Name [1] 302916 0
None
Address [1] 302916 0
None
Country [1] 302916 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 303514 0
New Zealand Health and Disability Ethics Committee
Ethics committee address [1] 303514 0
Ethics committee country [1] 303514 0
New Zealand
Date submitted for ethics approval [1] 303514 0
20/08/2021
Approval date [1] 303514 0
08/10/2021
Ethics approval number [1] 303514 0
21/STH/218

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 93926 0
Dr Rosemary Hall
Address 93926 0
Level 5 Grace Neill Block Wellington Hospital Private Bag 7902 Wellington 6021
Country 93926 0
New Zealand
Phone 93926 0
+6448062458
Fax 93926 0
Email 93926 0
[email protected]
Contact person for public queries
Name 93927 0
Amber Parry Strong
Address 93927 0
Level 5 Grace Neill Block Wellington Hospital Private Bag 7902 Wellington 6021
Country 93927 0
New Zealand
Phone 93927 0
+6448062458
Fax 93927 0
Email 93927 0
[email protected]
Contact person for scientific queries
Name 93928 0
Amber Parry Strong
Address 93928 0
Level 5 Grace Neill Block Wellington Hospital Private Bag 7902 Wellington 6021
Country 93928 0
New Zealand
Phone 93928 0
+6448062458
Fax 93928 0
Email 93928 0
[email protected]

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: At present this information is confidential due to possible commercial benefits.



What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.